Celgene’s (CELG) Revlimid Marches on

By Peter Geschek:Few biotech firms can match Celgene's (CELG) recent success: its shares have more than doubled in the past two years. The success can largely be credited to one drug: Revlimid, one of the most successful cancer therapies ever developed.

By George Liu: The Overview

Kevin Wilde submits:

By David Zanoni:If you're looking for an established biotech company with a number of FDA approved drugs already on the market, then Celgene Corporation (CELG) is one to consider. This $28.6 billion large-cap company has five established drugs for the treatment of various cancers currently being marketed. This takes the guesswork out of investing as compared to younger biotech companies which don't yet have any FDA approved drugs on the market.

By William Meyers: Celgene (CELG) provides a double dose of growth potential: further growth of its currently approved therapies and a rich pipeline with some therapies closing in on FDA approval and commercialization. Since I last wrote about Celgene on August 2, its stock price has risen from $57.29 to today's close of $64.29. Celgene's 52 week high is $68.25, reached on October 24th.

Zacks.com submits: Yesterday, Celgene Corporation (CELG) announced preliminary (unaudited) results for the fourth quarter of fiscal 2009 (ended December 31). The company earned 62 cents per share, beating the Zacks Consensus Estimate by 5 cents.

By Peter Geschek:In January at the J.P. Morgan conference Celgene (CELG) CEO Bob Hugin spelled out the company's long term plan for creating more blockbuster drugs and to double sales.

Jason Chew submits: Celgene (CELG) shares lost over 8% in regular trading to close at $55.64 on Monday after the company released clinical data for its multiple myeloma drug, Revlimid, at the American Society of Hematology (ASH) over the weekend. The stock lost another 3% after hours.